Crystal and electronic structure of two polymorphic modifications of famotidine.: An experimental and theoretical study

被引:37
作者
Ferenczy, GG
Párkányi, L
Angyán, JG
Kálmán, A
Hegedus, B
机构
[1] Gedeon Richter Ltd, H-1475 Budapest, Hungary
[2] Tech Univ Budapest, Dept Inorgan Chem, H-1111 Budapest, Hungary
[3] Hungarian Acad Sci, Chem Res Ctr, Inst Chem, H-1525 Budapest, Hungary
[4] Univ Henri Poincare, Chim Theor Lab, CNRS, UMR 7565,Inst Nancieien Chim Mol, F-54506 Vandoeuvre Nancy, France
来源
JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM | 2000年 / 503卷 / 1-2期
基金
匈牙利科学研究基金会;
关键词
famotidine; polymorphism; SCMP; crystal structure calculation;
D O I
10.1016/S0166-1280(99)00364-4
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
The antiulcer agent (i.e. a histamine H-2 receptor antagonist), famotidine is known to crystallize in two polymorphic modifications. A comparison of the two forms based on single crystal X-ray data and on quantum chemical calculations is presented. Form A is constructed from molecules with higher internal energy. The crystal field together with the intermolecular hydrogen bond network causes important deformation of the molecular charge densities with respect to that of the free molecules. This charge density deformation is more pronounced in form A as it is manifested by an increased dipole moment and by enhanced electrostatic and polarisation interaction energies. Thus the excess internal energy of form A with respect to form B is largely counterbalanced by the increased intermolecular interaction energy in the former modification. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:73 / 79
页数:7
相关论文
共 16 条
[1]  
Allen F.H., 1993, CHEM AUTOMAT NEWS, V8, P31
[2]  
Csikós É, 1999, EUR J ORG CHEM, V1999, P2119
[3]   THE DEVELOPMENT AND USE OF QUANTUM-MECHANICAL MOLECULAR-MODELS .76. AM1 - A NEW GENERAL-PURPOSE QUANTUM-MECHANICAL MOLECULAR-MODEL [J].
DEWAR, MJS ;
ZOEBISCH, EG ;
HEALY, EF ;
STEWART, JJP .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1985, 107 (13) :3902-3909
[4]  
Ferenczy GG, 1998, J COMPUT CHEM, V19, P38, DOI 10.1002/(SICI)1096-987X(19980115)19:1<38::AID-JCC3>3.0.CO
[5]  
2-#
[6]   STRUCTURE OF A NEW CRYSTALLINE FORM OF FAMOTIDINE [J].
GOLIC, L ;
DJINOVIC, K ;
FLORJANIC, M .
ACTA CRYSTALLOGRAPHICA SECTION C-STRUCTURAL CHEMISTRY, 1989, 45 :1381-1384
[7]   COMPARISON OF THE POLYMORPHIC MODIFICATIONS OF FAMOTIDINE [J].
HEGEDUS, B ;
BOD, P ;
HARSANYI, K ;
PETER, I ;
KALMAN, A ;
PARKANYI, L .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1989, 7 (05) :563-569
[8]   STRUCTURAL STUDY OF HISTAMINE H2-RECEPTOR ANTAGONISTS - 5 3-[2-(DIAMINO-METHYLENEAMINO)-4-THIAZOLYLMETHYLTHIO]PROPIONAMIDINE AND 5 3-[2-(DIAMINOMETHYLENEAMINO)-4-THIZOLYLMETHYLTHIO]PROPIONAMIDE DERIVATIVES [J].
ISHIDA, T ;
IN, Y ;
DOI, M ;
INOUE, M .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 1989, 45 :505-512
[9]  
KALMAN A, 1986, 10 EUR CRYST M WROCL, P69
[10]  
MAIN P, 1182 MULTAN U YORK E